OTCMKTS:EPRSQ - Epirus Biopharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.0012 +0.00 (+33.33 %)
(As of 09/21/2018 04:00 PM ET)
Previous Close$0.0009
Today's Range$0.0009 - $0.0012
52-Week Range$0.0003 - $0.0188
Volume12,063 shs
Average Volume30,403 shs
Market Capitalization$50,000.00
P/E RatioN/A
Dividend YieldN/A
Beta1.33
EPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company's pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. In addition, it is developing BOW080, a biosimilar version of Soliris for the treatment of ultra-rare blood disorders, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and BOW100, a biosimilar version of SIMPONI for the treatment of inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. The company has a license agreement with Sun Pharmaceutical Industries Ltd.; license and collaboration agreement with Livzon Mabpharm Inc.; and collaboration agreement with Polpharma S.A. The company was founded in 2011 and is headquartered in Boston, Massachusetts. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts.

Receive EPRSQ News and Ratings via Email

Sign-up to receive the latest news and ratings for EPRSQ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:EPRSQ
CUSIPN/A
Phone617-600-3497

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$580,000.00
Price / Sales0.05
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares26,180,000
Market Cap$50,000.00

Epirus Biopharmaceuticals (OTCMKTS:EPRSQ) Frequently Asked Questions

What is Epirus Biopharmaceuticals' stock symbol?

Epirus Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "EPRSQ."

How were Epirus Biopharmaceuticals' earnings last quarter?

Epirus Biopharmaceuticals Inc (OTCMKTS:EPRSQ) posted its quarterly earnings results on Tuesday, March, 15th. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.56) by $0.07. The biopharmaceutical company had revenue of $0.29 million for the quarter, compared to analyst estimates of $0.41 million. View Epirus Biopharmaceuticals' Earnings History.

Who are some of Epirus Biopharmaceuticals' key competitors?

Who are Epirus Biopharmaceuticals' key executives?

Epirus Biopharmaceuticals' management team includes the folowing people:
  • Mr. Jeff Kagy, VP of HR & Admin.
  • Jason Yap, Head of Global Regulatory Affairs and Sr. Director
  • Dr. Louis Boon Ph.D., Head of CLG, Bioassay & Process Devel.
  • Emile Van Corven Ph.D., Head of Analytical Devel. and Downstream PD
  • Dr. Mark Melville Ph.D., Sr. Director of Process Devel.

Has Epirus Biopharmaceuticals been receiving favorable news coverage?

Media coverage about EPRSQ stock has been trending somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Epirus Biopharmaceuticals earned a news impact score of 0.18 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 46.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future. View Recent Headlines for Epirus Biopharmaceuticals.

How do I buy shares of Epirus Biopharmaceuticals?

Shares of EPRSQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Epirus Biopharmaceuticals' stock price today?

One share of EPRSQ stock can currently be purchased for approximately $0.0012.

How big of a company is Epirus Biopharmaceuticals?

Epirus Biopharmaceuticals has a market capitalization of $50,000.00 and generates $580,000.00 in revenue each year.

How can I contact Epirus Biopharmaceuticals?

Epirus Biopharmaceuticals' mailing address is 699 BOYLSTON ST 8TH FLOOR, BOSTON MA, 02116. The biopharmaceutical company can be reached via phone at 617-600-3497 or via email at [email protected]


MarketBeat Community Rating for Epirus Biopharmaceuticals (OTCMKTS EPRSQ)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  63 (Vote Outperform)
Underperform Votes:  57 (Vote Underperform)
Total Votes:  120
MarketBeat's community ratings are surveys of what our community members think about Epirus Biopharmaceuticals and other stocks. Vote "Outperform" if you believe EPRSQ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPRSQ will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/21/2018 by MarketBeat.com Staff

Featured Article: Moving Average (MA)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel